Iovance Biotherapeutics, Inc. · 3 days ago
Senior Vice President, Global Corporate Controller
Iovance Biotherapeutics, Inc. is seeking a Senior Vice President, Global Corporate Controller to lead the company's global accounting team. The role involves overseeing accounting policies, managing financial reporting, and ensuring compliance with regulatory requirements while collaborating with executives across the organization.
Responsibilities
Provides strategic accounting, tax and investment leadership
Manages and develops a high performing finance team to ensure effective operation of the function in carrying out needed initiatives
Leads the Company’s financial close process, including preparation of financial statements and management reporting metrics and analysis in a timely manner
Continually evaluates opportunities to drive greater efficiencies and effectiveness in the monthly and quarterly accounting close process while ensuring a balanced workload within the organization
Responsible for external financial reporting process
Evaluate current accounting practices, systems and policies to ensure practices and financial reporting are continuously improving, and meet current and future requirements
Responsible for financial audits and provides recommendations for procedural improvements
Ensure compliance with all SEC, GAAP, FASB rules and regulations in addition to state, local and corporate policies, regulations and laws
Liaison with external independent auditors
Responsible for Sarbanes-Oxley compliance
Responsible for tax planning, analysis and compliance
Responsible for Treasury functions including investments within policy while ensuring highest possible return on investment and liquidity for near term operations
Collaborate closely with the legal team in regard to the Company’s governance processes, including leading the disclosure committee process
Direct and manage all aspects the Company’s tax reporting function ensuring timely and accurate regulatory filings globally as well as ensuring an appropriate tax provision
Ensures compliance with local, state, and federal budgetary and pricing reporting requirements, including Sunshine Act reporting
Provides accounting and business expertise to corporate development transactions, including collaboration agreements
Must adhere to Iovance Biotherapeutics’ core values, policies, procedures, and business ethics
Perform miscellaneous duties as assigned
Qualification
Required
BA/BS in Accounting/Finance
Minimum 15 years related financial accounting experience
CPA with “big four” experience required
Experience in public companies facing rapid growth while maintaining the highest standards in accounting practices
Proven ability to thoughtfully evaluate processes, identify opportunities for improvement and successfully execute on those plans
Excellent oral and written communication skills
Experience operating within a Sarbanes-Oxley control environment
Prior experience effectively managing external service providers to meet objectives and budgets
Ability to deal with business issues collaboratively with other department
Strong people management skills: reputation as a positive, highly motivated leader with a track record of recruiting and developing strong talent who have grown into senior managerial roles
Must be ‘hands-on' and able to work cross-functionally in a collaborative manner
Strong interpersonal skills and the ability to communicate effectively with people in diverse and different settings, including presentations to upper management
Personal presence, energetic, flexible team player and hands-on leader with the ability to manage in a dynamic environment
Strong attention to details
Time management and organizational skills
Ability to multi-task and effectively prioritize
Preferred
Public commercial-stage biotechnology or biopharmaceutical company experience highly preferred
Company
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Funding
Current Stage
Public CompanyTotal Funding
$1.58B2024-02-20Post Ipo Equity· $211M
2023-07-10Post Ipo Equity· $150M
2020-05-27Post Ipo Equity· $603.7M
Leadership Team
Recent News
2025-12-29
2025-12-07
2025-11-11
Company data provided by crunchbase